Thais Cristina Garbelini Salles1,2, Santiago Grau Cerrato3, Tatiana Fiscina Santana4, Eduardo Alexandrino Medeiros1. 1. Division of Infectious Diseases, Department of Internal Medicine, Paulista School of Medicine, Federal University of São Paulo, São Paulo, São Paulo, Brazil. 2. Hospital Santa Helena, Santo André, São Paulo, Brazil. 3. Autonomous University of Barcelona, Campus de la UAB, Bellaterra, Barcelona, Spain. 4. UnitedHealth Group, São Paulo, São Paulo, Brazil.
Abstract
OBJECTIVES: To identify factors associated with hospital admission and mortality within the first 30 days after enrolment in an outpatient parenteral antimicrobial therapy (OPAT) program, also analysing adequacy of the treatment regimen and clinical outcomes. PATIENTS AND METHODS: This was a retrospective cohort study conducted between October 2016 and June 2017 in the state of São Paulo, Brazil. Variables related to hospital admission and mortality were subjected to bivariate analysis, and those with a P<0.05 were subjected to multivariate analysis as risk factors. RESULTS: We evaluated 276 patients, of whom 80.5% were ≥60 years of age and 69.9% had more than one comorbidity. Of the patients evaluated, 41.3% had pneumonia and 35.1% had a urinary tract infection. The most common etiological agent, isolated in 18 (31.6%) cases, was Klebsiella pneumoniae, and 13 (72,2%) strains were carbapenem resistant. The OPAT was in accordance with the culture results in 76.6% of the cases and with the institutional protocols in 76.4%. The majority (64.5%) of the patients were not admitted, and a cure or clinical improvement was achieved in 78.6%. Multivariate analysis showed that, within the first 30 days after enrolment, the absence of a physician office visit was a predictor of hospital admission (P<0.001) and mortality (P = 0.006). CONCLUSIONS: This study demonstrated the viability of OPAT in elderly patients with pulmonary or urinary tract infections in an area with a high prevalence of multidrug-resistant bacteria and that a post-discharge physician office visit is protective against hospital admission and mortality.
OBJECTIVES: To identify factors associated with hospital admission and mortality within the first 30 days after enrolment in an outpatient parenteral antimicrobial therapy (OPAT) program, also analysing adequacy of the treatment regimen and clinical outcomes. PATIENTS AND METHODS: This was a retrospective cohort study conducted between October 2016 and June 2017 in the state of São Paulo, Brazil. Variables related to hospital admission and mortality were subjected to bivariate analysis, and those with a P<0.05 were subjected to multivariate analysis as risk factors. RESULTS: We evaluated 276 patients, of whom 80.5% were ≥60 years of age and 69.9% had more than one comorbidity. Of the patients evaluated, 41.3% had pneumonia and 35.1% had a urinary tract infection. The most common etiological agent, isolated in 18 (31.6%) cases, was Klebsiella pneumoniae, and 13 (72,2%) strains were carbapenem resistant. The OPAT was in accordance with the culture results in 76.6% of the cases and with the institutional protocols in 76.4%. The majority (64.5%) of the patients were not admitted, and a cure or clinical improvement was achieved in 78.6%. Multivariate analysis showed that, within the first 30 days after enrolment, the absence of a physician office visit was a predictor of hospital admission (P<0.001) and mortality (P = 0.006). CONCLUSIONS: This study demonstrated the viability of OPAT in elderly patients with pulmonary or urinary tract infections in an area with a high prevalence of multidrug-resistant bacteria and that a post-discharge physician office visit is protective against hospital admission and mortality.
Authors: Eliane Molina Psaltikidis; Everton Nunes da Silva; Maria Luiza Moretti; Plínio Trabasso; Raquel Silveira Bello Stucchi; Francisco Hideo Aoki; Luís Gustavo de Oliveira Cardoso; Christian Cruz Höfling; Luis Felipe Bachur; Danilo da Fontoura Ponchet; Maria Rosa Ceccato Colombrini; Cíntia Soarez Tozzi; Rosana Fins Ramos; Sandra Mara Queiroz Costa; Mariângela Ribeiro Resende Journal: Expert Rev Pharmacoecon Outcomes Res Date: 2018-11-05 Impact factor: 2.217
Authors: Jorge A Ramos-Castañeda; Alberto Ruano-Ravina; Raquel Barbosa-Lorenzo; Jaime E Paillier-Gonzalez; Javier C Saldaña-Campos; Diego F Salinas; Elkin V Lemos-Luengas Journal: J Infect Date: 2018-03-01 Impact factor: 6.072
Authors: Priscila Rosalba Oliveira; Cassia da Silva Felix; Vladimir Cordeiro de Carvalho; Arlete Mazzini Giovani; Rosangela Suarti Dos Reis; Marisa Beraldo; Edmir Peralta Albuquerque; Walter Cintra Ferreira; Jorge Dos Santos Silva; Ana Lucia Lei Lima Journal: Braz J Infect Dis Date: 2016-04-18 Impact factor: 3.257
Authors: Arturo Ortiz-Álvarez; Mónica A Delgado-Ramírez; Montserrat Cuevas-Zúñiga; Teresa Hernández-Carrera; David Moncada Barrón; Daniel Aguilar Zapata; Rafael R Valdez Vázquez; Juan Pablo Ramírez-Hinojosa; Ana Patricia Rodríguez-Zulueta Journal: Infect Drug Resist Date: 2018-12-28 Impact factor: 4.003